Abeona Therapeutics Net Income From Continuing Ops Over Time
| ABEO Stock | USD 5.08 0.19 3.61% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Abeona Therapeutics Performance and Abeona Therapeutics Correlation. Will Biotechnology sector continue expanding? Could Abeona diversify its offerings? Factors like these will boost the valuation of Abeona Therapeutics. If investors know Abeona will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Abeona Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share 1.21 | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
Investors evaluate Abeona Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Abeona Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Abeona Therapeutics' market price to deviate significantly from intrinsic value.
Understanding that Abeona Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Abeona Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Abeona Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income From Continuing Ops Analysis
Compare Abeona Therapeutics and related stocks such as Tenaya Therapeutics, Eledon Pharmaceuticals, and Puma Biotechnology Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TNYA | (26.2 M) | (26.2 M) | (26.2 M) | (26.2 M) | (26.2 M) | (26.2 M) | (26.2 M) | (26.2 M) | (26.2 M) | (26.2 M) | (38.4 M) | (72.7 M) | (123.7 M) | (127.7 M) | (111.1 M) | (100 M) | (105 M) |
| ELDN | (13.1 M) | (13.1 M) | (13.1 M) | (13.1 M) | (13.1 M) | (13.1 M) | (13.1 M) | (13.1 M) | (14.1 M) | (16 M) | (22.8 M) | (34.5 M) | (88 M) | (89.1 M) | (36.2 M) | (32.6 M) | (34.2 M) |
| PBYI | (10.2 M) | (10.2 M) | (74.4 M) | (54.7 M) | (142 M) | (239.3 M) | (276 M) | (292 M) | (113.6 M) | (75.6 M) | (60 M) | (29.1 M) | 2 K | 3.7 M | 30.3 M | 34.8 M | 36.6 M |
| HUMA | (66.5 M) | (66.5 M) | (66.5 M) | (66.5 M) | (66.5 M) | (66.5 M) | (66.5 M) | (66.5 M) | (66.5 M) | (66.5 M) | (66.5 M) | (26.5 M) | (12 M) | (89.4 M) | (148.7 M) | (133.8 M) | (127.1 M) |
| VYGR | (16.3 M) | (16.3 M) | (16.3 M) | (16.3 M) | (16.3 M) | (29.7 M) | (40.2 M) | (70.7 M) | (88.3 M) | (43.6 M) | 36.7 M | (71.2 M) | (46.4 M) | 132.3 M | (65 M) | (74.8 M) | (71 M) |
| ARCT | (10.5 M) | (10.5 M) | (10.5 M) | (10.5 M) | (32.8 M) | (1.9 M) | (24.6 M) | (10.9 M) | (21.8 M) | (26 M) | (72.1 M) | (203.7 M) | 9.3 M | 99.3 M | (80.9 M) | (72.8 M) | (69.2 M) |
| FHTX | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (51.1 M) | (68.8 M) | (101.3 M) | (108.9 M) | (103.2 M) | (86.6 M) | (78 M) | (81.9 M) |
| SGMT | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (11.4 M) | (24.4 M) | (30.5 M) | (26.9 M) | (45.6 M) | (41 M) | (39 M) |
| ASMB | (34.3 M) | (34.3 M) | (24.8 M) | (19.4 M) | (23.8 M) | (28.5 M) | (44.3 M) | (42.8 M) | (90.8 M) | (97.6 M) | (62.2 M) | (129.9 M) | (93.1 M) | (72.7 M) | (40.2 M) | (36.2 M) | (38 M) |
Abeona Therapeutics and related stocks such as Tenaya Therapeutics, Eledon Pharmaceuticals, and Puma Biotechnology Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Abeona Therapeutics | ABEO |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 6555 Carnegie Avenue, |
| Exchange | NASDAQ Exchange |
USD 5.08
Check out Abeona Therapeutics Performance and Abeona Therapeutics Correlation. To learn how to invest in Abeona Stock, please use our How to Invest in Abeona Therapeutics guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Abeona Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.